China said it will make the vaccine inexpensive for the world. That is pissing off the western pharma companies who were planning to make a tremendous amount of money with this vaccine.
Clinical human trials begin for COVID-19 vaccine in China
- Thread starter JSCh
- Start date
Yaseen1
ELITE MEMBER
- Joined
- Apr 1, 2014
- Messages
- 9,384
- Reaction score
- -5
- Country
- Location
u.s companies have habit of outsourcing vaccine manufacturing in china and I think all are cooperating in this regard
Actually not in pharmaceutical. US mainly buys the API from China makes it locally. But the vaccine is different. China already said it will make it affordable.
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
Chinese-developed inactivated vaccine has low rate of adverse reactions
By Hu Yuwei and Leng Shumei Source: Global Times Published: 2020/8/14 23:18:55
vaccine Photo:VCG
A Chinese-developed inactivated COVID-19 vaccine on Thursday revealed a low rate of adverse reactions for patients in phase one and two clinical trials while also demonstrating immunogenicity results. The interim analysis of two randomized clinical trials suggests a relatively better safety profile compared with other kinds of the same type of vaccine, researchers said in the latest report.
The report, published in peer-reviewed medical journal The Journal of the American Medical Association on Thursday, is the first formal clinical trial data for a COVID-19 inactivated vaccine, the vaccine producer China National Pharmaceutical Group (Sinopharm) told the Global Times in a statement on Friday.
Within seven days of injection, adverse reactions were reported by 48 (15.0 percent) of 320 participants in the trials, the report showed. All adverse reactions were mild, transient, and self-limiting, and did not require any treatment. No other adverse reactions were reported between days 8 and 28 after injection.
China's coronavirus vaccine R&D has always put safety as a top priority, and it will make sure all three phases of clinical trials are completed before formal approval, Tao Lina, a Shanghai-based vaccine expert, told the Global Times.
China is one of the countries that has unreservedly disclosed most data and results surrounding the safety and immune response of vaccine candidates, Tao said.
So far, at least three Chinese primary vaccine producers have delivered precise and detailed data for phase one and two trials.
Infographic: Global Times
The vaccine developed by Sinopharm is now undertaking its phase three trials in the UAE with more than 15,000 volunteers participating, while the early-stage trials for some remaining groups are still going ahead as planned, Sinopharm told the Global Times.
The optimal interval between injections and times for booster injections of the inactivated vaccine remains unclear, and the full analysis of the trial data with extended follow-up and other intervention groups is needed, according to the report.
Sinopharm told the Global Times that the results of phase one and two trials for another inactivated candidate they developed will be revealed in a few days.
The company estimated that an inactivated COVID-19 vaccine will be available on the market at the end of this year or early in 2021. The combined annual production capacity of the group will exceed 200 million doses when mass production is realized, to ensure the accessibility of COVID-19 vaccines, according to media reports.
By Hu Yuwei and Leng Shumei Source: Global Times Published: 2020/8/14 23:18:55
A Chinese-developed inactivated COVID-19 vaccine on Thursday revealed a low rate of adverse reactions for patients in phase one and two clinical trials while also demonstrating immunogenicity results. The interim analysis of two randomized clinical trials suggests a relatively better safety profile compared with other kinds of the same type of vaccine, researchers said in the latest report.
The report, published in peer-reviewed medical journal The Journal of the American Medical Association on Thursday, is the first formal clinical trial data for a COVID-19 inactivated vaccine, the vaccine producer China National Pharmaceutical Group (Sinopharm) told the Global Times in a statement on Friday.
Within seven days of injection, adverse reactions were reported by 48 (15.0 percent) of 320 participants in the trials, the report showed. All adverse reactions were mild, transient, and self-limiting, and did not require any treatment. No other adverse reactions were reported between days 8 and 28 after injection.
China's coronavirus vaccine R&D has always put safety as a top priority, and it will make sure all three phases of clinical trials are completed before formal approval, Tao Lina, a Shanghai-based vaccine expert, told the Global Times.
China is one of the countries that has unreservedly disclosed most data and results surrounding the safety and immune response of vaccine candidates, Tao said.
So far, at least three Chinese primary vaccine producers have delivered precise and detailed data for phase one and two trials.
The vaccine developed by Sinopharm is now undertaking its phase three trials in the UAE with more than 15,000 volunteers participating, while the early-stage trials for some remaining groups are still going ahead as planned, Sinopharm told the Global Times.
The optimal interval between injections and times for booster injections of the inactivated vaccine remains unclear, and the full analysis of the trial data with extended follow-up and other intervention groups is needed, according to the report.
Sinopharm told the Global Times that the results of phase one and two trials for another inactivated candidate they developed will be revealed in a few days.
The company estimated that an inactivated COVID-19 vaccine will be available on the market at the end of this year or early in 2021. The combined annual production capacity of the group will exceed 200 million doses when mass production is realized, to ensure the accessibility of COVID-19 vaccines, according to media reports.
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
AUGUST 17, 2020 / 4:06 PM / UPDATED 16 HOURS AGO
Testing of CanSino's COVID-19 candidate vaccine begins in Russia
Gabrielle Tétrault-Farber, Roxanne Liu
MOSCOW/BEIJING (Reuters) - Russia’s Petrovax has started a late-stage trial of a COVID-19 candidate vaccine from CanSino Biologics Inc in the country, records show, as the Chinese drug firm steps up testing abroad to close in on regulatory approval.
The Ad5-nCoV vaccine already has approval for use by China’s military after early and mid-stage trials, and further late-stage trials are being lined up for Mexico and Saudi Arabia.
CanSino last month said it was in talks for opportunities to launch late-stage - or Phase 3 - trials in Saudi Arabia, Russia, Brazil and Chile.
The company has won a patent approval from Beijing for the vaccine, Chinese state media reported on Sunday, citing documents from the country’s intellectual property regulator.
....
Testing of CanSino's COVID-19 candidate vaccine begins in Russia - Reuters
Ahmad Bhutta
FULL MEMBER
- Joined
- May 20, 2016
- Messages
- 659
- Reaction score
- -1
- Country
- Location
When will first Chinese vaccine be approved out of sinopharm sinovac and cansino?
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
China-developed COVID-19 vaccine ready to go onto market this Dec
Source: Global Times Published: 2020/8/18 10:01:13
vaccine Photo:VCG
Inactivated COVID-19 vaccine candidates developed by a Chinese pharmaceutical company are likely to be on the market by the end of December, at a price of less than 1,000 yuan ($144) for two doses.
The marketing review procedure will start after overseas phase three clinical trials have been completed, Liu Jingzhen, chairman of the China National Pharmaceutical Group (Sinopharm), was quoted as saying by media on Tuesday.
The price of the vaccines will not be high after they go onto the market, with every two doses costing less than 1,000 yuan, according to Liu.
Not all 1.4 billion Chinese people need to be vaccinated, Liu said, suggesting that students and those working in cities should take the injections while people who live in rural areas with comparatively smaller populations do not have to.
Two inactivated vaccine candidates developed by institutes under Sinopharm separately in Beijing and Wuhan were delivered into phase three clinical trials in the United Arab Emirates in June.
Liu himself has also been injected with two doses of one of the inactivated candidates. So far, he said he felt “no side effects.”
A workshop in Beijing able to produce 120 million doses per year has passed biological safety inspection from the related national authorities and is ready for production. Another workshop of Sinopharm in Wuhan is able to produce 100 million doses per year, Liu noted.
Source: Global Times Published: 2020/8/18 10:01:13
Inactivated COVID-19 vaccine candidates developed by a Chinese pharmaceutical company are likely to be on the market by the end of December, at a price of less than 1,000 yuan ($144) for two doses.
The marketing review procedure will start after overseas phase three clinical trials have been completed, Liu Jingzhen, chairman of the China National Pharmaceutical Group (Sinopharm), was quoted as saying by media on Tuesday.
The price of the vaccines will not be high after they go onto the market, with every two doses costing less than 1,000 yuan, according to Liu.
Not all 1.4 billion Chinese people need to be vaccinated, Liu said, suggesting that students and those working in cities should take the injections while people who live in rural areas with comparatively smaller populations do not have to.
Two inactivated vaccine candidates developed by institutes under Sinopharm separately in Beijing and Wuhan were delivered into phase three clinical trials in the United Arab Emirates in June.
Liu himself has also been injected with two doses of one of the inactivated candidates. So far, he said he felt “no side effects.”
A workshop in Beijing able to produce 120 million doses per year has passed biological safety inspection from the related national authorities and is ready for production. Another workshop of Sinopharm in Wuhan is able to produce 100 million doses per year, Liu noted.
Ahmad Bhutta
FULL MEMBER
- Joined
- May 20, 2016
- Messages
- 659
- Reaction score
- -1
- Country
- Location
Oh God DecemberChina-developed COVID-19 vaccine ready to go onto market this Dec
Source: Global Times Published: 2020/8/18 10:01:13
vaccine Photo:VCG
Inactivated COVID-19 vaccine candidates developed by a Chinese pharmaceutical company are likely to be on the market by the end of December, at a price of less than 1,000 yuan ($144) for two doses.
The marketing review procedure will start after overseas phase three clinical trials have been completed, Liu Jingzhen, chairman of the China National Pharmaceutical Group (Sinopharm), was quoted as saying by media on Tuesday.
The price of the vaccines will not be high after they go onto the market, with every two doses costing less than 1,000 yuan, according to Liu.
Not all 1.4 billion Chinese people need to be vaccinated, Liu said, suggesting that students and those working in cities should take the injections while people who live in rural areas with comparatively smaller populations do not have to.
Two inactivated vaccine candidates developed by institutes under Sinopharm separately in Beijing and Wuhan were delivered into phase three clinical trials in the United Arab Emirates in June.
Liu himself has also been injected with two doses of one of the inactivated candidates. So far, he said he felt “no side effects.”
A workshop in Beijing able to produce 120 million doses per year has passed biological safety inspection from the related national authorities and is ready for production. Another workshop of Sinopharm in Wuhan is able to produce 100 million doses per year, Liu noted.
im in travel business and we r totally screwed already
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
Sinopharm’s Covid-19 Vaccine to Start Human Trials in Peru After UAE
ZHANG YUSHUO
DATE: 2 HOURS AGO / SOURCE: YICAI
Sinopharm’s Covid-19 Vaccine to Start Human Trials in Peru After UAE
(Yicai Global) Aug. 20 -- China National Pharmaceutical Group will kick off phase-three clinical trials of its inactivated Covid-19 vaccine candidate in Peru after doing so in the United Arab Emirates in June.
Local health authorities have given the Chinese firm, better known as Sinopharm, a permit for the tests, the Beijing-based firm said in a statement on Sina Weibo today.
Sinopharm expects to bring its first inactivated coronavirus vaccine to market by the end of this year, pricing the necessary two doses at less than CNY1,000 (USD144) in total, Chairman Liu Jingzhen said earlier this month.
ZHANG YUSHUO
DATE: 2 HOURS AGO / SOURCE: YICAI
Sinopharm’s Covid-19 Vaccine to Start Human Trials in Peru After UAE
(Yicai Global) Aug. 20 -- China National Pharmaceutical Group will kick off phase-three clinical trials of its inactivated Covid-19 vaccine candidate in Peru after doing so in the United Arab Emirates in June.
Local health authorities have given the Chinese firm, better known as Sinopharm, a permit for the tests, the Beijing-based firm said in a statement on Sina Weibo today.
Sinopharm expects to bring its first inactivated coronavirus vaccine to market by the end of this year, pricing the necessary two doses at less than CNY1,000 (USD144) in total, Chairman Liu Jingzhen said earlier this month.
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
Pakistan to conduct trials of Chinese coronavirus vaccine
Issued on: 18/08/2020 - 16:20
Modified: 18/08/2020 - 16:18
The trials will be conducted at several medical facilities across Pakistan Arif ALI AFP
Karachi (AFP)
Pakistan regulators have approved final-phase testing of a Chinese-made vaccine against the coronavirus, officials said Tuesday, in the country's first ever clinical trial of its kind.
According to Pakistan's National Institute of Health (NIH), regulators have approved the testing of a vaccine under development by CanSinoBio and the Beijing Institute of Biotechnology China.
The medication is already undergoing Phase 3 trials -- or large-scale testing on humans -- in China, Russia, Chile and Argentina. Saudi Arabia will also take part, NIH said.
"This will be the first ever Phase 3 clinical trial for any vaccine in Pakistan," the NIH said in a statement.
Pakistan's inclusion in the trials would help it secure "preferential vaccine supply and pricing", it added.
The trials will be conducted at several medical facilities across Pakistan, including the large Indus Hospital in Karachi.
"Hopefully we will come out with the vaccine within three to four months," Abdul Bari, who heads the Indus Hospital, told AFP.
The coronavirus has claimed more than 6,000 lives in Pakistan but cases have been dropping for several weeks.
© 2020 AFP
Issued on: 18/08/2020 - 16:20
Modified: 18/08/2020 - 16:18
Karachi (AFP)
Pakistan regulators have approved final-phase testing of a Chinese-made vaccine against the coronavirus, officials said Tuesday, in the country's first ever clinical trial of its kind.
According to Pakistan's National Institute of Health (NIH), regulators have approved the testing of a vaccine under development by CanSinoBio and the Beijing Institute of Biotechnology China.
The medication is already undergoing Phase 3 trials -- or large-scale testing on humans -- in China, Russia, Chile and Argentina. Saudi Arabia will also take part, NIH said.
"This will be the first ever Phase 3 clinical trial for any vaccine in Pakistan," the NIH said in a statement.
Pakistan's inclusion in the trials would help it secure "preferential vaccine supply and pricing", it added.
The trials will be conducted at several medical facilities across Pakistan, including the large Indus Hospital in Karachi.
"Hopefully we will come out with the vaccine within three to four months," Abdul Bari, who heads the Indus Hospital, told AFP.
The coronavirus has claimed more than 6,000 lives in Pakistan but cases have been dropping for several weeks.
© 2020 AFP
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
Global Times @globaltimesnews
China state-affiliated media
Chinese vaccine producer #Sinopharm signed a COVID19 inactivated vaccine cooperation agreement with #Morocco on Thursday, a new partnership after its phase-3 clinical trials cooperation with #UAE and #Peru.
9:23 PM · Aug 20, 2020
China state-affiliated media
Chinese vaccine producer #Sinopharm signed a COVID19 inactivated vaccine cooperation agreement with #Morocco on Thursday, a new partnership after its phase-3 clinical trials cooperation with #UAE and #Peru.
9:23 PM · Aug 20, 2020
Ahmad Bhutta
FULL MEMBER
- Joined
- May 20, 2016
- Messages
- 659
- Reaction score
- -1
- Country
- Location
I think enough trials have been done already , please release the vaccine now . December is too far
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
Global Times @globaltimesnews
China state-affiliated media
#Chinese #vaccine producer #Sinopharm signed a #COVID19 vaccine cooperation agreement with Argentina on Friday to carry out phase III clinical trials in the country, joining Peru and Morocco. https://bit.ly/2COZ6UB
2:00 PM · Aug 22, 2020
China state-affiliated media
#Chinese #vaccine producer #Sinopharm signed a #COVID19 vaccine cooperation agreement with Argentina on Friday to carry out phase III clinical trials in the country, joining Peru and Morocco. https://bit.ly/2COZ6UB
2:00 PM · Aug 22, 2020
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
China's first COVID-19 vaccine made from insect cells approved for clinical trialsHK, Macao scientists eye low-cost mass production of new vaccine
By Zhang Hui Source: Global Times Published: 2020/8/3 20:55:57
Samples of the COVID-19 inactivated vaccine are seen at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 10, 2020.Photo:Xinhua
As scientists globally race to develop effective COVID-19 vaccines, scientists from Hong Kong and Macao special administrative regions announced a breakthrough in developing a recombinant COVID-19 vaccine on Monday, indicating that the mass production of the vaccine is feasible at a low cost in the future.
They have evaluated the potential of a candidate vaccine based on the receptor-binding domain (RBD) of SARS-CoV-2, and found that a recombinant vaccine could induce a potent functional antibody response in immunized mice, rabbits and non-human primates as early as seven to 14 days after a single dose.
The research, conducted by the Hong Kong Polytechnic University (PolyU) and the Macau University of Science and Technology (M.U.S.T.) in collaboration with Chinese mainland institutions, was recently published in the scientific journal Nature, in a paper entitled, "A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity."
Zhang Kang, a professor from the Faculty of Medicine of M.U.S.T., the author of the study, said at Monday's press conference that the biotechnology method used in creating the recombinant vaccine is mature, as many vaccines on the market, such as human papillomavirus (HPV) and flu vaccines, adopted the same method, and that makes the recombinant vaccine feasible for mass production.
"Manufacturing the most vaccines at the least cost is a key issue in vaccine production, and this vaccine could be mass produced at a low cost," Zhang said. He said that the vaccine will be available in Hong Kong, Macao and other regions and countries.
Johnson Lau, adjunct professor of the Department of Applied Biology and Chemical Technology at PolyU, told the Global Times at the press conference that the team has started engaging with several collaborators for mass production, and some contracts have been signed.
The vaccine will start human clinical trials in "at most months, if not weeks," Lau said.
Five Chinese COVID-19 vaccines have entered the clinical trial stage - one adenovirus vector vaccine and four inactivated vaccines - accounting for 40 percent of clinical-stage vaccines worldwide, according to the Ministry of Science and Technology.
Tao Lina, a Shanghai-based vaccine researcher, told the Global Times on Monday that some domestically made COVID-19 vaccines have entered phase three clinical trials, which usually takes about two to three months. These vaccines may be available for mass production by the end of the year, he said.
Recombinant vaccines are much easier to be mass produced at a lower cost compared to inactivated vaccines, Tao said.
Russia plans to launch a mass vaccination campaign in October, and the US company Moderna announced in late July it began phase three trials of a COVID-19 vaccine in the US.
Reuters reported on Friday, citing an unnamed US security official, that China-backed hackers tried to steal "valuable data" from Moderna.
Tao said such allegations are purely "nonsense," as many Western vaccine companies including Moderna used the gene sequencing date published by China to develop their vaccines.
Source: Global Times Published: 2020/8/22 21:12:14
Photo:VCG
China's first recombinant protein COVID-19 vaccine made from insect cells has been approved for clinical trials by the National Medical Products Administration, media reported on Saturday.
Developed by the State Key Laboratory of Biological Therapy of Sichuan University affiliated West China Hospital, the vaccine uses insect cells to multiply in the culture medium and introduces the gene of COVID-19 into insect cells, which means the cell can be used as a factory to produce high-quality recombinant vaccine proteins and purify them for refinement.
The vaccine was tested on monkeys and other animals, and was found to have a good protective effect against COVID-19 infection, with no obvious side effects. The technology is expected to make it simple to quickly bring a vaccine to the market with mass production, Chinanews.com reported.
The safety of using insects to produce recombinant protein vaccines has been demonstrated by the successful development and marketing of cervical cancer and influenza vaccines in Europe and the US, media reported.
In April this year, The West China Hospital of Sichuan University, the vaccine research team and a biological company established a new company, which is planning and designing the vaccine production line with an annual output of over 100 million needles by independent efforts, Chinanews.com reported.
A Chinese inactivated COVID-19 vaccine has started phase-3 clinical trials in Peru on Thursday, Xinhua News Agency reported. Two months before, China's inactivated COVID-19 vaccine received approval for phase-3 clinical trials in the United Arab Emirates on June 23.
Observers believe that when a vaccine is available, China would provide vaccines to countries that cooperated with it in clinical trials at a cost, or donate vaccines to these countries.
Last edited:
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
China to prioritize Mekong countries for COVID-19 vaccine
Source: Xinhua| 2020-08-24 11:23:35|Editor: huaxia
BEIJING, Aug. 24 (Xinhua) -- China will give priority to providing COVID-19 vaccines to Mekong countries once a vaccine is developed and put into use, Chinese Premier Li Keqiang said Monday.
Li made the remarks when attending the third Lancang-Mekong Cooperation (LMC) leaders' meeting via video link.
China will set up special funds to promote public health under the framework of the LMC Special Fund, and continue to provide anti-epidemic materials and technical support to Mekong countries, Li said.
Stressing the significance of solidarity and cooperation to the global fight against the pandemic, Li said China is willing to work with Mekong countries to support the work of the World Health Organization.
Source: Xinhua| 2020-08-24 11:23:35|Editor: huaxia
BEIJING, Aug. 24 (Xinhua) -- China will give priority to providing COVID-19 vaccines to Mekong countries once a vaccine is developed and put into use, Chinese Premier Li Keqiang said Monday.
Li made the remarks when attending the third Lancang-Mekong Cooperation (LMC) leaders' meeting via video link.
China will set up special funds to promote public health under the framework of the LMC Special Fund, and continue to provide anti-epidemic materials and technical support to Mekong countries, Li said.
Stressing the significance of solidarity and cooperation to the global fight against the pandemic, Li said China is willing to work with Mekong countries to support the work of the World Health Organization.
Similar threads
